Embodiments of the present invention relate generally to intraocular lenses. More particularly, embodiments of the invention relate to accommodative and disaccommodative intraocular lens systems (AD-IOL) and a shape shifting flexible optic adapted to couple with a zonular capture haptic system. The combined features of this flexible optic and zonular capture system haptic system result in a novel, dual mode AD-IOL in which the optic shifts both in shape and in position inside the eye, mimicking the behavior of the natural lens, with the small optic adapted to function in the closed and fibrosed capsular bag that results from conventional cataract surgery.
Under normal conditions, a healthy human eye focuses on near and distant objects by contraction and relaxation of the ciliary muscle thereby contracting and releasing the tension on the zonules in the eye. The elastic forces of the eye cause disaccommodation and the elastic recoil of the lens caused accommodation. The balance between these two opposing elastic forces is modulated by the neurologically controlled contraction of the ciliary body. The contraction of the ciliary muscle releases zonular tension (accommodative state) and allows the lens to return to a more globular or spherical resting shape. The relaxation of the ciliary muscle increases tension on zonules and elastic forces in the eye tissue overcome the inherent lens elasticity and result in stretching the lens equator and flattening the lens curvature (disaccommodative state).
In certain instances, for example when age-related opacification of the lens (cataract) interferes with vision, the natural crystalline lens of the eye needs to be removed. Generally, the natural lens is replaced with an artificial one, for example, an intraocular lens (IOL).
Unfortunately, conventional IOLs, and currently FDA approved accommodative IOLs, may be unable to provide sufficient spatial displacement of the lens along the optical axis to provide an adequate amount of accommodation for near vision. For an accommodative IOL to be effective, it preferably provides equally for both accommodation and disaccommodation.
In conventional extracapsular cataract surgery, the crystalline lens matrix is removed by phacoemulsification through a curvilinear capsularhexis leaving intact the thin walls of the anterior and posterior capsules, together with zonular ligament connections to the ciliary body and ciliary muscles. An intraocular lens is then placed in the capsular bag, which collapses around the IOL. A conventional monofocal IOL is rigidly fixated in the nonmoving and fibrosed capsular bag. The position of the IOL in the capsular bag is neither in the accommodated or disaccommodated state, but somewhere in between, as determined by the amount of bag contraction and IOL design. This position is called “effective lens position” and it is utilized in calculating the power of the desired optic. The power of the optic determines the single point of perfectly focused vision, often selected at a practical arm length range.
Conventional axial shifting accommodative intraocular lenses (AIOL) rely on the interaction of the ciliary muscle with the zonule and capsule and the vitreous fluid compartment to induce movement of the optic of the AIOL along its optical axis. Typically, the AIOL is secured within the capsular bag that attempts to translate both the rotational and the radial stretching force exerted by the zonules in an attempt to achieve the desired axial displacement of the optic.
However, during the post-implantation fibrotic healing process, the anterior capsule fuses with the posterior capsule to form a rigid capsular disc, a strait jacket for the AIOL. Loss of elasticity of the capsular disc results and constrains the amount of movement, both centrifugal and rotational, that can be generated by the eye disaccommodation forces transmitted to the IOL via zonules or by the elastic recoil of the intraocular lens within the bag and therefore, leads to a decrease in the amount of axial displacement of the lens that can be achieved. The lens neither accommodates nor disaccommodates.
Various lens systems have been designed to address this loss of accommodation. One type of passive-shift single-optic lens, the only accommodative lens currently marketed in the United States, was designed to move forward under vitreous humor pressure when presumably the ciliary muscle contracts and forces vitreous forward. Even the limited amount of accommodative amplitudes generated by this lens immediately after surgery may be lost within the first few weeks or month after surgery as capsular fibrosis ensues and sometimes the movement is backwards. No passive shift AIOLs are marketed in the US that translate ciliary muscle contraction into forward shift of the optic by direct mechanical action of the haptics.
Accommodative lens designs with single or multiple optic lens assemblies have been disclosed, for example, in U.S. Patent Publication Nos. 2009/0125106, 2005/0209692, 2007/0156236, 2009/0005866, 2007/0005136, and 2009/0248154. Dual optic lenses retain the problem of capsular fibrosis and loss of amplitude/movement even though they are theoretically expected to provide a significant amount of accommodation. One such IOL received regulatory approval in Europe, but was abandoned and withdrawn from the market because of poor and unpredictable clinical results. This lens did not receive FDA approval and currently this approach appears to have been abandoned.
More recently, a lens systems that employs an active-shift mechanism using repulsive mini-magnets as a means of making accommodation partially independent of the zonules and mechanical properties of the capsular bag was disclosed (see U.S. Patent Publication Nos. 2009/0204210 and 2007/0118216). Still other methods of achieving accommodation include introduction of a polymerizable fluid with a desired refractive index into the capsular bag (lens refilling). Extensive investigation into the feasibility of these methods is still needed.
U.S. Patent Publication No. 2009/0234449 discloses an intraocular lens having an accommodating element that is in contact with a substantial portion of the zonular contact region of the ciliary body; the accommodating element is positioned relative to optical element and configured to cooperate with the ciliary muscle, the zonules and/or the vitreous pressure in the eye to effect a shape change to the optical element. According to the '449 publication, prior art multiple lens systems can be cumbersome and may also require an axial displacement unachievable with a collapsed capsular bag and resulting ineffective accommodative mechanisms.
More recently, a lens system has been described that employs a novel zonular capture haptic (ZCH) (see U.S. Patent Publication No. 2011/0307058, incorporated herein by reference in its entirety). The lens system provides improved accommodation via a two stage procedure. In the implantation step, Stage 1, a specially designed sectionable haptic, i.e., a ZCH, is inserted between the anterior and posterior lens capsules and it is maintained in a restrained configuration. Sufficient time is allowed for fusion and fibrosis of the two capsule leaflets to each other, thereby permanently trapping the haptic components between the capsules. During Stage 2, activation surgery may be subsequently performed to section the fused capsular bag between individual haptic components and release the restraining mechanism, thereby breaking the mechanical restraint that typically limits movement of other “in the bag” implanted IOLs.
The basis for embodiments of the present invention is an accommodative-disaccommodative IOL (AD-IOL) with flexible shape shifting optic and zonular capture haptics having a dual mode of action: both an axial shift of the optic and a shape shift of the optic, driven by the dynamic balance between the action of the zonular capture haptics on the flexible optic and the shape memory of the optic and or haptic system. Embodiments of the present invention assemble together numerous individual elements, some that have been previously described separately as components of different modality IOLs, into a novel, comprehensive, and cohesive design. This unique design is specifically constructed to function in a closed and fibrosed capsular bag as is encountered after conventional cataract surgery, and results in an AD-IOL having a size similar to that of conventional IOLs. The shape shifting of the optic allows for a far greater range of accommodation than provided by the axial shift component alone. Both components act synergistically to increase the amount of accommodation obtained. The unavoidable biological response of healing and scarring after cataract surgery is not avoided, but rather utilized for the proper function of this dual mode AD IOL, which is actuated by the radial pull of the zonules. In contrast, the prior art describes attempts to prevent closure of the bag and to use the unfused capsules, open bag, to compress mechanical structures that transmit force to various optic designs, or to use the direct compression of the ciliary muscle.
The ratio between the volume and surface area of a shape shifting flexible optic changes as the optic geometry changes from accommodated to disaccommodated configuration. Embodiments of the dual mode AD-IOL described herein are adapted to alter this ratio in several ways so that the optic can attain its required degree of sphericity.
The AD-IOL enables both accommodation and disaccommodation to take place under the force load produced by zonules in the post-surgical fibrosed capsular bag, specifically as it has been measured and verified experimentally. The balance between accommodation and disaccommodation is controlled by the ciliary muscle and is transmitted via zonules, as a radial pull, to the zonular capture components of the haptic system and then to the AD-IOL system. The AD-IOL responds to the disaccommodative force exercised on it by zonules that counter the inherent accommodative elasticity of the AD-IOL, which is configured to return to a fully accommodated configuration at rest. The ciliary body contraction can then modulate the disaccommodation force exercised on the AD-IOL by zonules in a measured way under neural control, thereby allowing the AD-IOL to assume in a desired configuration based on the balance of accommodation and disaccommodation forces. The zonular capture haptics have been previously described in U.S. Patent Publication No. 2011/0307058. Embodiments of the present invention include an intraocular lens system that includes a shape-shifting flexible optic, i.e., an optic of variable power in which the power can be changed by the forces of accommodation or disaccommodation produced in the eye and that can return to the original power when these forces subside. It may also include a zonular capture haptic system. The shape-shifting flexible optic may include a small, fluid-filled, elastic thin walled optic vesicle, with characteristics adapted to be altered by action of haptics attached thereto. In use, the optic vesicle may be acted upon by the action of the haptic system during accommodation or disaccommodation. This action alters the shape of the optic vesicle thereby changing its dioptric power.
Both the optic and the haptic system may have shape memory that is calculated to generate elastic recoil of the AD-IOL to the accommodated state when zonular tension is reduced. The shape memory features of the haptic and/or optic systems cooperate to result in the ability of the AD-IOL to respond to the actual small forces generated inside the eye subsequent to cataract surgery and capsular bag closure and fibrosis.
In an aspect, embodiments of the invention relate to a dual mode accommodative-disaccommodative intraocular lens (dual mode AD-IOL) including a haptic system having a plurality of closed-loop haptics having shape memory. A shape-shifting flexible optic includes an anterior optic capsule and a posterior optic capsule, each of the two capsules having a fusion zone and the fusion zones of the two capsules being fused together, thereby defining therebetween an optic vesicle, the optic vesicle being filled with a fluid. The haptics are attached to the optic, allowing an action of the haptics to alter a shape of the optic, The shape-shifting flexible optic has a diameter of ≤8 mm. The dual mode AD-IOL, at rest, is in a fully accommodated configuration as a result of at least one of the shape memory of the haptic system and a shape-shifting capability of the flexible optic. A restraining component is sized and configured to immobilize the haptic in at least one of a flatter angle and a larger diameter in a disaccommodated configuration of the AD-IOL, when compared to the accommodated configuration.
One or more of the following features may be included. The closed-loop haptics may be at least one of trapezoidal and T-shaped. The dual-mode AD-IOL may include an optic ring that connects the haptics to each other and to the optic. The haptics may be attached to the optic by a portion of each haptic being embedded in the optic at the fusion zone. Each closed-loop haptic may be configured to adapted to transmit to the optic radial pull created by zonular tension during disaccommodation of the AD-IOL. Each closed-loop haptic may be configured to adapted to return to a set shape during accommodation of the AD-IOL.
The restraining component may be a restraining tab disposed on a haptic or an optic ring, a restraining hole defined by a haptic portion, a restraining hole defined by an optic in a fusion zone thereof, a cross bar on a haptic arm, a restraining ring, and/or a suture.
A ring-shaped plate may be embedded between an anterior optic capsule and a posterior optic capsule of the optic. The ring-shaped plate may define at least one concentric ring of holes. The ring-shaped plate may include a material having shape memory. The ring-shaped plate (i) may be more rigid than the optic and (ii) may provide structural stability to the optic. The ring-shaped plate may include a non-reflective surface.
Each of the closed-loop haptics may include a sinusoidal-shaped equatorial portion. Each of the closed-loop haptics may include a first connecting feature and the optic may include a second connecting feature adapted to engage with the first connecting feature.
The first connecting feature may be a ring defined by each of the closed-loop haptics, the second connecting feature may include a plurality of pegs defined by the optic, and each ring may be sized and configured to receive a peg.
The first connecting feature may include a T defined by each of the closed-loop haptics, and the second connecting feature may include a T-shaped groove defined by the optic and sized and configured to receive each T. Each of the closed-loop haptics may be shape set to contribute to axial shift and shape shift of the optic.
The plurality of closed-loop haptics may be defined by a continuous loop configured to change diameter in response a change of diameter of a capsular bag in which the dual-mode AD-IOL is implanted, thereby diminishing irregular tension on the optic from zonules.
Each of the closed-loop haptics may include spaced-apart ends proximate the optic, thereby enabling expansion of the closed-loop haptics.
The haptic system may include at least two optic rings, each optic ring including two closed-loop haptics, the optic rings being disposed over the optic and configured to rotate to overlay the haptics of a first optic ring over the haptics of a proximate optic ring, to reduce a profile thereof to facilitate loading of the dual-mode AD-IOL in an injector.
At least one closed-loop haptic may include a radial segment and a paddle being disposed on the radial segment configured to compress a portion of the optic.
A sum of accommodative memory of the optic and the haptic system may be accommodative at rest.
A sum of at least an accommodative memory or a disaccommodative memory of the optic and the haptic system may be less than 1 gram force. A sum of at least an accommodative memory or a disaccommodative memory of the optic and the haptic system may be less than zonular tension.
The anterior and posterior optic capsules may be fused with a bonding material and the fusion zone may define a channel configured to receive excess bonding material.
A change in a shape of the flexible optic may change a ratio of a surface area of the optic vesicle to a volume of the optic vesicle changes and the haptic system may change size and shape to accommodate the change in the ratio.
One of the optic capsules may have a thick, rigid optical zone carrying a fixed refractive power including astigmatic correction. An axis of the rigid optical zone may be marked externally. The rigid optical zone may function as a centration and fixation zone to the haptic system.
One of the optic capsules may include a thinner, more easily distorted flexion zone disposed proximate a central optical zone. One of the optic capsules may have thicker, less easily distorted piston zones disposed within or proximate to the flexion zone optic zone and adapted to push fluid toward the center of the optic vesicle. The thicker piston zone may include a plurality of structures adapted to capture and affix radial arms of the haptic system.
Each fusion zone may be adapted to embed individual haptics of the haptic system.
The optic vesicle may be filled with a constant volume of the fluid at no more than a minimally stretched configuration, to cause minimal resistance to shape shifting.
The optic vesicle may have shape memory.
The fluid may have an index of refraction greater than an index of refraction of water, e.g., substantially the same as an index of refraction of the optic vesicle.
The haptic system may be adapted to fit within an IOL injection system, e.g., adapted to roll into a cylinder.
The AD-IOL may be adapted to be restrained in a flattened, stretched out, disaccommodated configuration at implantation and during capsular bag fusion and fibrosis.
The AD-IOL may be adapted to be released by an external laser application. The external laser application may section simultaneously both the restraining device and the fused capsular bag of an eye at the same time by radial cuts between haptics, the radial cuts extending from edges of the eye's anterior capsule towards an equator of the eye's capsular bag for a distance defined to produce a desired amount of release in stiffness of the eye's fibrosed capsular bag.
In another aspect, embodiments of the invention relate to a method for implanting a dual-mode AD-IOL. The method includes providing an AD-IOL including a haptic system having a plurality of closed-loop haptics having shape memory. A shape-shifting flexible optic includes an anterior optic capsule and a posterior optic capsule, each of the two capsules having a fusion zone and the fusion zones of the two capsules being fused together, thereby defining therebetween an optic vesicle, the optic vesicle being filled with a fluid. The haptics are attached to the optic, allowing an action of the haptics to alter a shape of the optic, The shape-shifting flexible optic has a diameter of ≤8 mm. The dual mode AD-IOL, at rest, is in a fully accommodated configuration as a result of at least one of the shape memory of the haptic system and a shape-shifting capability of the flexible optic. A restraining component is sized and configured to immobilize the haptic in at least one of a flatter angle and a larger diameter in a disaccommodated configuration of the AD-IOL, when compared to the accommodated configuration. The AD-IOL is implanted into an eye of a patient. A capsular bag of the eye is allowed to fuse through the haptics. The haptics are released by making radial cuts therebetween, the radial cuts extending from edges of the eye's anterior capsule towards an equator of the eye's capsular bag for a distance defined to produce a desired amount of release in a stiffness of the eye's fibrosed capsular bag.
In one embodiment, during accommodation, the haptic arms flex closer to the axis of the AD-IOL and squeeze the optic vesicle and cause it to become more rounded, i.e., to have more convex surfaces with greater dioptric power. During disaccommodation, the same haptic arms may exert a pulling action on the optic vesicle, causing it to stretch laterally, and consequently have a less convex surface, i.e., lower dioptric power.
The optic vesicle may be manufactured from two separate components, an optic anterior capsule and an optic posterior capsule. The two are fused at their outer edges allowing the space in between to be filled with fluid. The fluid may have a higher index of refraction than water thereby conferring the biconvex optic vesicle a positive dioptric power. Ideally, the index of refraction of the fluid matched the index of refraction of the optic vesicle, thereby eliminating and optical interference from the internal surfaces of the optic vesicle.
In one embodiment, the optic vesicle is designed to be relatively small and comparable in size or volume to a standard monofocal IOL optic, with an overall disaccommodated diameter of 8 mm or less mm and optical zones of 6 mm or less, in a human sized AD-IOL. The same optic vesicle embodiment, sized for an experimental model consisting of a Rhesus monkey eyes, has an overall diameter of 6 mm and an optical zone of 4 mm.
In one embodiment, one of the optic capsules, for example the anterior capsule, has an optical zone that is thicker or more rigid such that it does not alter its shape under the forces of accommodation or disaccommodation produced in the eye. This is the prescription component of the IOL adapted to correct an individual patient refractive error. It may be shaped to confer a fixed amount of the refractive power of the IOL and also possibly an astigmatic correction power if desired. The axis of such a astigmatic correction may be marked on the edges of this thicker optical zone or structure fixing the optic.
In one embodiment the opposite capsule, for example the posterior optic capsule, remains maximally thin and flexible to allow maximum bowing or flattening under pressure or tension, from the arms of the haptic system, and thus confer an additional number of diopters during accommodation. This is the accommodative component of the optic.
In one embodiment the volume of fluid filling the optic vesicle is constant in all AD-IOLs and the curvature of the thin flexible optic zone is predictable. The variations in power required for different eyes are controlled by the fixed power of the rigid optic zone, the prescription component.
In one embodiment the optic anterior capsule and or the posterior capsule have a more rigid zone that is thicker and shaped to fit within the haptic optic ring or fusion zone or other haptic devices for secure centration. In other embodiments, ridges, protuberances or other structures ensure centration in the optic ring or other haptic devices.
In one embodiment the optic anterior or posterior capsule has a thinner, maximally flexible zone that corresponds to the haptic flexion zone, and allows a change in the shape of the optic vesicle with minimum resistance. This flexion zone is peripheral to the optic zone. In another embodiment the flexion zone has external pegs for direct attachment of haptic proximal ends.
In one embodiment the optic anterior or posterior capsule has thicker zones, blocks with grooves to incorporate and fix the haptic radial arms. Additional thicker and more rigid zone may exist in between haptics. The overall rigidity of this zone allows it to also function as a piston zone, driving fluid centrally to cause a bowing of the thinner capsule optical zones. This zone is peripheral to the flexion zone.
In one embodiment, the haptic arms have wide plate like structures adapted to press on the optic flexion zones.
In one embodiment, the outermost zone of the optic anterior capsule, on its underside, has a fusion zone designed to become fused to a corresponding zone on the posterior capsule of the optic vesicle. Channels or groves allow excess bonding material to pool at the fusion zone and not spread out. One or more fluid filling channels may be built into the thicker blocks zone or other suitable locations.
In one embodiment, columns or ridges or ribs are built internally between the anterior and posterior capsule to diminish movement of the more rigid prescription zone during accommodation. Such structure have the added benefit of adding structural stability to the shape of a flexible optic and limit distortion.
In one embodiment the optic vesicle is filled with fluid to the full non-stretch or minimally stretched volume, where the capsules of the optic vesicles are shaped set for a disaccommodated configuration. The accommodative elastic force of the AD-IOL is provided primarily by the haptic system.
In one embodiment the optic vesicle is constructed separately and independently from the haptic system and the two are assembled together by pressing the optic vesicle into the haptic structure. The optic vesicle can be snapped into and secured to the haptic system by precise geometry and mechanical snug fit, or parts of it may be incorporated into the fusion zones, or it may be additionally secured after assembly with additional polymer or adhesive added to the grooves containing haptic arms or other haptic attaching components.
In one embodiment, the haptic system is maintained disaccommodated after IOL implantation with a loop, or a ring of polypropylene or other similar biocompatible materials, that can be transacted and rendered inoperative by the use of a laser, for example a YAG or femtosecond laser, or surgical instruments. Such loop may be fixated to positions of AD-IOL, so that if the restraining loop is cut, the segments of the loop remain attached to the AD-IOL outside of the optical zone, and need not be removed from the eye.
In one embodiment the optic may incorporate an artificial iris element that blocks the passage of light through the peripheral zone of the optic from being transmitted to the inside of the eye. The peripheral zone undergoes purposeful mechanical alterations that reshape the central optical zone, but in themselves can cause undesirable image distortions and artifacts.
In one embodiment, the optic may incorporate a mechanical reinforcement element, that stabilizes the shape of the optic vesicle and may have shape memory or superelasticity.
In one embodiment, the optic vesicle may have an integrated haptic restraining component that is separate from the haptic system.
In yet another embodiment, the incorporated artificial iris, reinforcing element, and the haptic restraining element may coexist in a single element, and this element may have a non-reflective surface.
In one embodiment, the haptic system may be adapted to be rolled into a narrow cylinder to facilitate its injection into the capsular bag at the time of surgery. Such adaptations may include, but not be limited to altering the number of haptic arms, altering the connections between the haptic arms, altering the shapes or sizes of loops that allow the eye's anterior and posterior capsule to fuse through and thus fixated the haptics, and any other feature known to one of skill in the art.
In another embodiment, two or more optic rings with two haptics each are superimposed and can rotate about the optic. Before loading the AD-IOL in an injector, the top ring or rings are rotated so that their haptics overlay the bottom ring, in effect forming a two-haptic AD-IOL for the purpose of limiting injector size. Once implanted into the eye, the surgeon rotates the top ring or rings so that all four or more haptics are uniformly distributed in the capsular bag.
In certain embodiments, the optic vesicle, restraining ring, and haptics may each include a biocompatible plastic, such as polypropylene, poly(methyl methacrylate), polyamide, nylon, polyester, polyvinylidene fluoride, and/or silicone. The haptics and optic securing components and restraining components may each include a biocompatible metal or alloy, such as stainless steel and/or nickel titanium alloy.
In one embodiment, the optic vesicle is filled with a biocompatible fluid with an index of refraction greater than water, such as but not limited to silicone oil.
In another embodiment of the invention, the optic vesicle is filled to a non-stretch or minimally stretched volume and shape set for accommodated configuration. In this embodiment, the action of zonular capture haptics is primarily to stretch the optic vesicle to its disaccommodated, flatter shape. The elastic accommodative force is contained primarily in the fluid-filled vesicle, not in the haptic structure.
In this embodiment, the AD-IOL is implanted in a stretched disaccommodated configuration, by the action of a restraining device.
In another embodiment, the elastic accommodative force is contained in the shape memory of both the fluid-filled vesicle and in the haptic structure, and their elastic recoil may be additive or subtractive to result to an overall level that can be disaccommodated by zonular tension, at about 1 gram of force or less per individual haptic.
In another embodiment, the optic vesicle can alter its surface area to volume ratio as it changes from accommodated to disaccommodated state to conform to the required geometry by stretching or un-stretching the optic flexible zone or by pumping in or drawing our fluid under the action of the haptics.
All patent applications, patents, and other references cited herein are hereby incorporated by reference in their entirety into the present disclosure.
In ophthalmology, the term “haptic” refers to a structure that extends out from an optic element of an intraocular lens, usually for holding the lens in place within the capsular bag of the eye. Herein, “haptics” are sometimes referred to as “zonular capture haptics,” or collectively as a “zonular capture haptic system,” or simply “haptic system” and refer to structures or material that not only assist with placement and centration of the lens within the capsular bag to transmit zonular movement to the lens, but also permit secure fixation in between or to the anterior or posterior capsule following removal of the natural lens and placement of the artificial lens. A haptic system may also include an optic retainer for holding an optic. An “optic retainer” is a portion of the haptic system that holds the optic, e.g., a ring, pins, or other attachment mechanism.
The zonular capture haptics 100 are connected to each other and the optic 105 by an optic ring 135, which may be a single continuous structure or may be made of multiple segments or elements designed to hold the optic 105. The optic ring 135 or optic ring segments may attach to the optic 105 by a snug fit to parts of the optic 105, by being fused to the outside of the optic 105, or by being contained in part or in whole inside the fusion zone of the optic 105 or other parts of the optic 105 adapted for this purpose.
In
In use, restraining tabs 130 are utilized to lock the haptic structure at implantation and for some weeks afterwards in a disaccommmodated configuration, until such a time that the capsular bag fusion and fibrosis has completed. The haptic arms 115 are maintained in a horizontal position by virtue of a loop of biocompatible material, such as a suture woven under haptic arms 115 and over restraining tabs 130, or a ring 155 such as the one in
Referring to
In one embodiment the optic anterior capsule 180 has a central optical zone 165 that is thicker, more rigid and fits snugly inside of the optic ring of the haptic structure. Such optical surface may provide a predetermined customizable power for the IOL that is specific for each patient, for example 15 D vs. 16.5 diopters, and may have an astigmatic correction component as well, if so desired. This is the prescription component of the IOL. The axis of this surface is marked on the edges of the optic zone or the haptic structures holding the optic 105 in place. In one iteration, the greater thickness of the fixed optical surface, for example 200-500 microns, is elected to make it sufficiently rigid as to not be altered in the shape by the actions of the haptics 100 or shifting fluid. Immediately peripheral to the optical zone 165, a thinner flexion zone 160, generally situated under the haptic flexion zone 110, facilitates a shape change for the optic 105 under the squeezing or pulling effect of the radial haptic arms 115 during accommodation. The flexion zone 160 may be as thin as 25-50 microns. The peripheral aspect of the flexion zone 160 may be more rigid 170 and function as a piston zone and has more rigid components, shaped as blocks 175 to retain and fix the distal part of the haptic arms 115. The haptic arms 115 may fit snugly, e.g., snap in, in the grooves or notches within or in between these blocks and may be additionally secured with a biocompatible polymer or adhesive when the lens is assembled. The outermost edge of the optic anterior capsule, on the underside of the structure, is designed as a fusion zone 190 to the corresponding fusion zone of the optic posterior capsule 195.
In addition to securing the optic to the haptic radial arms, so that the optic vesicle can be both compressed and stretched by the flexion and extension of the haptic arms, such rigid sections also function as piston zones, forcing the fluid displaced by compression during accommodation toward the center of the optic vesicle. Additional piston zones may be placed between haptics as needed.
In one embodiment, the optic posterior capsule 185 is thin, e.g., having a thickness of 25 microns to 50 microns for example, and fused on its outer most edge 195 to the optic anterior capsule. The central portion of the optic posterior capsule is the optical zone 200 and may or may not have an additional molded refractive shape and it represents a variable power optical zone, the accommodating component of the IOL.
Referring to
During accommodation, when the haptic arms 115 flex toward the axis of the IOL, fluid in the optic 105 is displaced centrally by the piston zones of the optic anterior capsule, resulting in additional bowing of the optic posterior capsule and an increase in its refractive power. The optic posterior capsule in this embodiment is sufficiently thin to undergo shape shifting with minimal resistance to the haptic arms 115. In another embodiment, the thicker, fixed optical zone may be placed on the optic posterior capsule and the variable optical zone on the optic anterior capsule. In such an embodiment, additional pegs or ridges or other fixation structure (not shown) may be built on the optic anterior capsule to allow its centration on the haptic optic ring 135.
In another embodiment, the entire optic 110 is manufactured in a rotational mold machine that creates a single vesicle at once and eliminates the need to fuse separately molded capsules.
Referring to
Referring to
In one embodiment, the volume of fluid inside the IOL is calculated to be constant fill, to a non-stretch or minimally stretched vesicle volume. This allows shape shifting of the vesicle with minimal resistance. The fill of the optic vesicle bows out the variable power zone, the accommodating component, on the optic posterior capsule, for example, to a predetermined and fixed power for each corresponding haptic configuration. This power added to the power of the rigid optical zone, the prescription component, on the opposite capsule constitutes the IOL power for that particular haptic configuration, for distance or disaccommodated vision. Additional power is obtained during accommodation by the compression caused by the flexion of the haptics 100, elastic recoil of the optic vesicle, or both, which bows the optic posterior capsule further and, in doing so, increasing its power by up to 14 diopters. One or more filling channels can be constructed within the thicker regions of the optic vesicle such as the pistons blocks or haptic retaining blocs, or any other suitable locations. These channels are utilized to fill the optic vesicle with fluid and remove any inadvertent air bubbles during assembly.
Referring to
The zonular capture haptics 100′ may be separate as in
Referring to
After implantation, the ring 155 may be deactivated by cutting it in sections with an external, non-invasive laser or with surgical instruments, or disconnecting it from the IOL, and it may or may not need to be removed from the eye, based on multiple possible configurations.
The restraining ring 155 may, as seen in
The restraining ring may 155 be cut simultaneously with radial cuts in the fused capsular bag of the eye, between haptic elements. Such cuts may extend from the edge of the anterior capsulotomy surgically performed in the eye's anterior capsule at the time of surgical implantation, towards the equator of the eye's capsular bag, for a predetermined distance measured to cause a sufficient release in the stiffness of the eye's fibrosed capsular bag to obtain the desired amount of movement of the AD-IOL of embodiments of the invention.
Immediately peripheral to the central optical zone 165 of the anterior capsule 180 is a flexion zone 160 of the optic 105, which includes protruding pegs 240 for attachment to haptic attachment rings 245 (described below). The pegs 240 may be circular or non-circular in shape, may protrude at a direction parallel to the visual axis, or a different direction, may have a wider base to support the haptic attachment rings, and may have a wider mushroom like cap to prevent the pegs 240 from being dislodged under tension. In an embodiment, the pegs 240 are cylindrical with a diameter of 100-500 microns and a height of 200-500 microns, with one peg 240 per haptic attachment point, preferably 6 pegs or more, preferably 8. The overall number and dimensions of the restraining pegs 240 are governed by the mechanical properties and dimension of the optic and haptic components balanced against design and usage limitations. The greater the number of pegs 240, the more uniform the zonular tension that is applied to the optic 105, the lower the mechanical load on each peg 240, and the greater the complexity of the AD-IOL construction and usage. Alternatively, the geometry of the connection between the proximal end of the haptic 100 and the flexible optic 105 may have an alternative geometry, such as a T or anchor-shaped haptic end in a matching groove, or other configurations known in the art.
The region of the flexion zone 160 between pegs 240 may be thicker and may be sinusoidal in configuration, continuously or in separate segments, to distribute the pulling vectors on the optical zone more uniformly and over a broader zone of the optical zone, without hindering the ability of the flexion 160 and optical zone to expand to a wider diameter during disaccommodation. In an exemplary embodiment, the flexion zone 160 may have a thickness selected from a range of 25 to 50 microns, and a width selected from a range of 200 to 500 microns.
Peripheral to the flexion zone 160 is a fusion zone 290 of the anterior optic, where the anterior optic is fused to a fusion zone 195 of the posterior optic 185. The fusion zone 290 of the anterior optic may have a width selected from a range of 100 to 1000 microns. An overhanging lip 250 disposed on the outer periphery of the anterior optic fusion zone, or alternatively on the posterior one, allows for better centration and a more secure seal when the elements are assembled. This anterior optic component provides the presbyopic correction.
The posterior optic element 185 is substantially thicker, to resist distortion, and carries the prescription refractive power, the power that corrects the individual patient's aphakic refraction. A thickness of the posterior optic element 185 may be selected from a range of 100 to 500 microns. The posterior optic element 195 has a posterior optic fusion zone, with a width selected from a range of 100 to 1000 microns. Generally the smallest dimension that allows the prescription optical zone to resist flexion during accommodation is preferable, as it reduces the overall bulk of the AD-IOL.
A ring-shaped plate 255 made of shape memory metal, such as nitinol, is embedded between the anterior and posterior optic fusion zones. The plate 255 extends from the outer edge of the optical zone towards to periphery and up to the overhanging lip in the fusion zone, being completely enclosed within the fused silicone capsules. The area of the plate 255 under the flexion zone 160 is solid, while the area within the fusion zone 290 is perforated by one or more concentric rings of holes, with each having a diameter of, e.g., 100 to 500 microns. The holes are preferably spaced 50 to 200 microns apart, to facilitate the use of a suture, as described below. The plate 255 may be 0.001 to 0.002″ in thickness. The surface of the plate 255 may be treated to be dark, or non-reflective, by means of laser surface modification, or chemical or pigment deposition. The dark or non-reflective surface reduces light scatter inside the eye, which may cause image degradation, patient discomfort, and/or a cosmetically objectionable mirror-like surface in the pupil of the patient when the patient's pupil is dilated, for example in a low light environment. A similar treatment, for the same reasons, may be applied to the optic ring and haptics.
In an embodiment, the ring-shaped plate 255 has three separate functions. A pericentric zone 260, located underneath the flexion zone 160 of the anterior capsule functions as an artificial iris to block peripheral stray light and prevent image distortion and degradation through the flexion and fusion zones of the optic 105. The size of the hole in the center of the ring-shaped plate 255 becomes an effective pupil, allowing only light traveling through the optical zones of the optic 105 to reach the patient's retina. The size of the hole preferably generally matches the diameter of the optical zones and may be, for example, 4 to 7 mm in diameter, to allow the maximum amount of non-distorted light to pass through to the retina.
Immediately peripheral to the pericentric zone 260 is disposed a restraining zone 265 that defines one or more rings of concentric restraining holes 270 sized and distributed to facilitate restraining the haptic in a disaccommodated position at implantation and several weeks thereafter, described below. Accordingly, the restraining holes 270 extend through the anterior capsule, holes defined in the ring-shaped plate 255, and the posterior capsule, or may be completely covered by a continuous layer of silicone elastomer. The restraining holes 270 preferably have a diameter of 100 to 500 microns, and are spaced 50 to 200 microns apart. Preferably, at least 2-4 holes are disposed in a vicinity of each peg 240. The ideal number and size of the restraining holes 270 have been discussed above. The remainder of the holes 270, not in position to restrain the haptic arms 115, are generally larger to allow for more adhesive contact between the fusion zones of the anterior and posterior optic while maintaining structural integrity of the plate 255 and not allowing too much stray light to travel to the back of the eye.
The haptics 100 in this embodiment are zonular capture haptics made of shape memory metal, such as nitinol, and can be as thin as 0.002″. The arms of the haptics 115 move in the same plane with the fusion zone, which corresponds to the plane of axial pull by zonules in the closed and fused capsular bag. The individual haptics 100 allow room for radial capsular sectioning between the haptics 100. The flexion zone of the haptic 110 is short and at a relatively steep angle to allow the haptic peg rings 245 to approach the optic pegs 240 for fixation. The optic peg rings may be circular or a different shape, generally matching the shape of the pegs 240, and sized to make a tight fit or squeeze on the pegs 240. Cross bars 275 on the haptic arms 115 allow restraining of the haptics 100 to a disaccommodated configuration by suturing across the optic fusion zone, through the restraining holes, as described below. In addition to the restraining function, the holes allow direct contact between the anterior and posterior capsules and with bonding material to form a more secure fusion of the anterior and posterior optics. The short and steep flexion zones 110 of the haptic 100 convert most of the radial zonular pull into a shape shifting effect on the optic 105 with a smaller effect towards an axial shift of the optic 105. The distal portion of each haptic 100 has a sinusoidal shape 125 to allow this end of the haptic 100 to expand and contract circumferentially and in step with the change in diameter of the capsular bag during accommodation and disaccommodation, so that the haptic 100 does not impede the movement of the fused capsular bag. For a similar reason, the two proximal ends of each haptic 100, attached to the pegs of the optic 105, are not connected to each other. Rather, the proximal haptic ends form an open loop, so that the pegs and haptic ends can move to a larger diameter when the anterior capsule stretches during disaccommodation. The haptic 100 is shape set for the accommodated configuration.
In use, a suture is passed across the fused, silicone peripheral capsules, through the restraining holes, and around each cross bar 275 on the arm of the haptic 115 to create a loop to immobilize the haptic 100 in stretched disaccommodated position. The suture may be made from any biocompatible material known in the art. Such a suture may be cut by non-invasive external laser application, such as YAG or femtosecond laser. The cut suture segments may be trapped in the silicone fusion zone and may not necessarily be removed from the eye. Once the suture is cut, the haptic 100 is free to move.
The third purpose of the embedded plate 255 is to enhance the structural stability and shape memory of the flexible silicone optic, to ensure that it returns to a desired shape after compression or deformation during the implantation step, for example by being forced to go through a small incision injector. Similarly, an optic 105 sufficiently thin to be shape shifted by weak zonular forces has some preferred areas of stable geometry during haptic movement, to direct all movement energy to the accommodating element and not the reminder of the flexible optic.
In the embodiment illustrated in
The AD-IOL is manufactured from four separate components that are assembled together. The two optics elements (anterior and posterior capsules) are molded as individual components from silicone elastomer or a similar biocompatible material. The individual haptics and the ring plate are laser cut from a nitinol sheet of desired thickness, which can be as thin as 0.002-0.001 inches. The haptic is heat shaped to its accommodated configuration. The surface of the nitinol parts is chemically treated to increase biocompatibility and remove any laser-induced irregularities, for example by a chemical or electrochemical pickling or oxidizing bath or other processes known in the art. The ring plate is positioned in place in the posterior optic element with a bonding material in the fusion zone, such as uncured silicone elastomer or silicone adhesive. Additional bonding agent is added and the anterior capsule is added with the overhanging lip covering the seam between the ring plate and the posterior optic capsule. The three components are clamped and heat treated to cure the bonding material. A needle enters the optic tangentially through the fusion zone, and silicone oil is injected into the central cavity; any air bubbles are meticulously removed. The silicone fill is adjusted to achieve the desired optical power with minimal or no stretching of the thin anterior capsule. When the needle is removed, the external ostium of the self-sealing needle passage is further sealed with bonding material. The haptic is placed in position by grasping the optic pegs and pulling them through the corresponding holes in the haptics. Additional bonding material is applied as a mushroom cap to the pegs, or the optic rings can be secured with miniature rivets, sutures, or other devices know in the art. Alternatively, the optic vesicle is manufactured as a single piece by rotation molding or a similar technique and the ring plate is fused externally to either the posterior or anterior fusion zone.
An alternative haptic configuration uses a continuously looped nitinol wire, with loops capturing the attachment optic pegs, restraining holes and equator of the capsular bag in patterns similar to intravascular stents. This continuous loop haptic makes contact with more points in the equator of the fused capsular bag and distributes uneven lateral loads throughout the haptic system to decrease the risk of optical distortion of the very thin anterior capsule. In particular, referring to
The haptic system includes an optic ring 135, radially extending restraining tabs 130 and radially extending closed looped haptics. Each haptic 100 has an equatorial region 120 that becomes captured in the fused capsular bag, and has a generally sinusoidal shape 125 to allow this end of the haptic 100 to expand and contract circumferentially and in step with the change in diameter of the capsular bag during accommodation and disaccommodation, so that the haptic 100 does not impede the movement of the fused capsular bag. Proximal to the equatorial region are radial arms 115 and then a flexion zone 110 that attaches them to the optic ring. The haptics 100 are shaped set to be angled posteriorly, as much as at 45 degrees in resting position. In contrast to the haptic structure depicted in
The anterior capsule 180 includes a central optical zone 165 and a thicker fusion zone 290 in the periphery, adapted to bond to the fusion zone of the posterior optic. The fusion zones have rounded edges to create channels or spaces 295 where excess bonding material can bead and collect rather than spread toward the optical surface. The central anterior capsule is made of shape memory silicone elastomer and may be as thin as 25-50 microns. The thickness of the optical zone may be uniform throughout or change gradually from the center to the periphery. The anterior capsule provides the accommodative component of the IOL.
The posterior capsule 185 is substantially thicker, to resist distortion during accommodation, and it also has a central optical zone 200 and a peripheral fusion zone 195. The fusion zone has similar rounded edges to allow excess bonding material to bead in circumferential spaces 295 and not spread toward the optical surface or haptic arms 115. The optical zone carries the patient's prescription power, the power needed to correct the patient's aphakic refractive error including possibly astigmatic error. The axis of the astigmatic correction is marked externally. The anterior equatorial zone of the posterior capsule has compressible 285 and non-compressible 300 zones. The compressible zones 285 are immediately below the paddle 280 elements of the haptics 100 and are very thin, so that they can be easily squeezed by the haptics 100. The non-compressible zones 300 are located under the restraining tabs of the haptic 100. Here, the equatorial zones of the anterior and posterior capsules are fused with pillars or ribs 305. This imparts structural rigidity to the posterior optical surface when pressure is applied by haptics 100 to the compressible zones 295.
In this embodiment, zonular axial pull causes flattening of the haptic structure and posterior axial shift. When the zonular tension abates, the haptics 100 flex posteriorly towards the visual axis and axially shift the optic anteriorly and also shape shift the optic geometry. The flexible optic of this embodiment is fluid filled and adapted to change to a more accommodated, convex configuration of the thin anterior optic capsule when the haptics 100 press on thin peripheral compression zones shifting fluid centrally and anteriorly. The surface area of the thin anterior optic capsule, the accommodating element, may be altered, or stretched during accommodation, when additional volume of fluid is shifted be the haptics 100 compression and the optical zone becomes more spherical. These changes maintain the proper volume/surface area ratio required by the geometry of the accommodated optic 105. The thickness of the compression zones may be as little as 25-50 microns, and the compression zone may be thinner and more stretchable than the anterior optical zone.
The internal cavity 205 is filled with fluid having a greater index of refraction than water, such as silicone oil for example, and preferably with the same index of refraction as the elastomer used for the anterior and posterior capsule elements. The cavity 205 is filled to its disaccommodated shape, where the optical zone is generally not stretched but the compression zones may or may not be stretched, depending on their thicknesses and desired balance of opposing forces. Biocompatible sutures or rings are used to suspend the haptics 100 to the restraining tabs, giving the haptics 100 a generally horizontal configuration, in the same plane with the optic ring and the closed capsular bag prior to implantation. The sutures or rings are amendable to being sectioned by an external, non-invasive laser, such as YAG or femtosecond. After several weeks post implantation, once the capsular bag has closed, fused and fibrosed, trapping the haptics within, the suture or ring is cut and radial cuts in the capsular bag may also be performed between haptics 100. This allows the haptic system to move in response to zonular tension. During accommodation, the zonular tension abates, the haptics 100 can move towards their resting state, vaulting posteriorly and compressing the compression zones in between. This compression shifts the internal fluid centrally and forward and bows the anterior optical surface to a more convex, accommodated configuration. When zonular tension resumes during disaccommodation, the haptics 100 are pulled apart and the stretch of the anterior optical zone pushes fluid down and out and fills the compression zones.
The two optical components are made of shape memory elastomer, such as silicone, and preferably of a different silicone family than the fluid filling the optic vesicle. They are molded separately and assembled together with the haptic ring and bonded. The fusion zones ensure both centration of the two optical components and also the trapping of the optic ring between the two optical components, which helps to stabilize the structure of the IOL.
The haptic system is made of nitinol, laser cut from a sheet that may be as thin as 0.0001″ or 0.0002″, shape set to its resting accommodated configuration and chemically surface treated to increase its biocompatibility and reduce laser induced irregularities. Once the three components are assembled and bonded, the cavity is filled with fluid, such as silicone oil, with a needle passing tangentially through a thicker area of the lens.
While several aspects of the present invention have been described and depicted herein, alternative aspects may be effected by those skilled in the art to accomplish the same objectives. Accordingly, it is intended that the appended claims cover all such alternative aspects as fall within the true spirit and scope of the invention.
This application claims priority to and the benefit of U.S. Provisional Patent Application Ser. No. 62/378,737 filed on Aug. 24, 2016, the disclosure of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3975779 | Richards et al. | Aug 1976 | A |
3979780 | Boniuk | Sep 1976 | A |
3991426 | Flom et al. | Nov 1976 | A |
4053953 | Flom et al. | Oct 1977 | A |
4056855 | Kelman | Nov 1977 | A |
4124905 | Clark | Nov 1978 | A |
4149279 | Poler | Apr 1979 | A |
4262370 | Hartstein | Apr 1981 | A |
4373218 | Schachar | Feb 1983 | A |
4463457 | Kelman | Aug 1984 | A |
4527294 | Heslin | Jul 1985 | A |
4534069 | Kelman | Aug 1985 | A |
4575373 | Johnson | Mar 1986 | A |
4581032 | Grandon | Apr 1986 | A |
4581033 | Callahan | Apr 1986 | A |
4588406 | Fedorov et al. | May 1986 | A |
4666446 | Koziol et al. | May 1987 | A |
4685922 | Peyman | Aug 1987 | A |
4693717 | Michelson | Sep 1987 | A |
4718904 | Thornton | Jan 1988 | A |
4738680 | Herman | Apr 1988 | A |
4781719 | Kelman | Nov 1988 | A |
4787903 | Grendahl | Nov 1988 | A |
4790847 | Woods | Dec 1988 | A |
4842601 | Smith | Jun 1989 | A |
4871363 | Kelman | Oct 1989 | A |
4878910 | Koziol et al. | Nov 1989 | A |
4888012 | Horn et al. | Dec 1989 | A |
4888015 | Domino | Dec 1989 | A |
4892543 | Turley | Jan 1990 | A |
4932966 | Christie et al. | Jun 1990 | A |
4932968 | Caldwell et al. | Jun 1990 | A |
4936850 | Barrett | Jun 1990 | A |
4944082 | Jones et al. | Jul 1990 | A |
4950288 | Kelman | Aug 1990 | A |
4955894 | Herman | Sep 1990 | A |
4963148 | Sulc et al. | Oct 1990 | A |
4995879 | Dougherty | Feb 1991 | A |
5104590 | Blake | Apr 1992 | A |
5108429 | Wiley | Apr 1992 | A |
5185107 | Blake | Feb 1993 | A |
5192319 | Worst | Mar 1993 | A |
RE34424 | Walman | Oct 1993 | E |
5282851 | Jacob-LaBarre | Feb 1994 | A |
5288293 | O'Donnell, Jr. | Feb 1994 | A |
5306297 | Rheinish et al. | Apr 1994 | A |
5326347 | Cumming | Jul 1994 | A |
5366500 | Schneider et al. | Nov 1994 | A |
5423929 | Doyle et al. | Jun 1995 | A |
5476514 | Cumming | Dec 1995 | A |
5489302 | Skottun | Feb 1996 | A |
5496366 | Cumming | Mar 1996 | A |
5507806 | Blake | Apr 1996 | A |
5527415 | Doyle et al. | Jun 1996 | A |
5549668 | O'Donnell, Jr. | Aug 1996 | A |
5562731 | Cumming | Oct 1996 | A |
5571177 | Deacon et al. | Nov 1996 | A |
5578081 | McDonald | Nov 1996 | A |
5593436 | Langerman | Jan 1997 | A |
5607472 | Thompson | Mar 1997 | A |
5674282 | Cumming | Oct 1997 | A |
5683456 | Blake | Nov 1997 | A |
5702441 | Zhou | Dec 1997 | A |
5728155 | Anello et al. | Mar 1998 | A |
5728156 | Gupta et al. | Mar 1998 | A |
5769889 | Kelman | Jun 1998 | A |
5782911 | Herrick | Jul 1998 | A |
5800532 | Lieberman | Sep 1998 | A |
5803925 | Yang et al. | Sep 1998 | A |
5843187 | Bayers | Dec 1998 | A |
5855605 | Herrick | Jan 1999 | A |
5964802 | Anello et al. | Oct 1999 | A |
5984962 | Anello et al. | Nov 1999 | A |
6013101 | Israel | Jan 2000 | A |
6015435 | Valunin et al. | Jan 2000 | A |
6027531 | Tassignon | Feb 2000 | A |
6048364 | Skottun | Apr 2000 | A |
6051024 | Cumming | Apr 2000 | A |
6053944 | Tran et al. | Apr 2000 | A |
6083261 | Callahan et al. | Jul 2000 | A |
6096077 | Callahan et al. | Aug 2000 | A |
6096078 | McDonald | Aug 2000 | A |
6110202 | Barraquer et al. | Aug 2000 | A |
6139576 | Doyle et al. | Oct 2000 | A |
6143027 | Ratner et al. | Nov 2000 | A |
6152959 | Portney | Nov 2000 | A |
6171337 | Galin | Jan 2001 | B1 |
6176878 | Gwon et al. | Jan 2001 | B1 |
6179843 | Weiler | Jan 2001 | B1 |
6190410 | Lamielle et al. | Feb 2001 | B1 |
6197058 | Portney | Mar 2001 | B1 |
6197059 | Cumming | Mar 2001 | B1 |
6200342 | Tassignon | Mar 2001 | B1 |
6200344 | Lamielle et al. | Mar 2001 | B1 |
6217612 | Woods | Apr 2001 | B1 |
6224628 | Callahan et al. | May 2001 | B1 |
6228115 | Hoffmann et al. | May 2001 | B1 |
6241777 | Kellan | Jun 2001 | B1 |
6251312 | Phan et al. | Jun 2001 | B1 |
6261321 | Kellan | Jul 2001 | B1 |
6280449 | Blake | Aug 2001 | B1 |
6299641 | Woods | Oct 2001 | B1 |
6302912 | Bernau | Oct 2001 | B1 |
6306167 | Bernau et al. | Oct 2001 | B1 |
6358280 | Herrick | Mar 2002 | B1 |
6387126 | Cumming | May 2002 | B1 |
6398809 | Hoffmann et al. | Jun 2002 | B1 |
6406494 | Laguette et al. | Jun 2002 | B1 |
6413262 | Saishin et al. | Jul 2002 | B2 |
6413277 | Neuhann | Jul 2002 | B1 |
6423094 | Sarfarazi | Jul 2002 | B1 |
6425917 | Blake | Jul 2002 | B1 |
6428574 | Valunin et al. | Aug 2002 | B1 |
6432246 | Blake | Aug 2002 | B1 |
6443984 | Jahn et al. | Sep 2002 | B1 |
6443985 | Woods | Sep 2002 | B1 |
6451056 | Cumming | Sep 2002 | B1 |
6461384 | Hoffmann et al. | Oct 2002 | B1 |
6464725 | Skotton | Oct 2002 | B2 |
6475240 | Paul | Nov 2002 | B1 |
6482229 | Gwon et al. | Nov 2002 | B1 |
6488707 | Callahan et al. | Dec 2002 | B1 |
6488708 | Sarfarazi | Dec 2002 | B2 |
6488709 | Barrett | Dec 2002 | B1 |
6494911 | Cumming | Dec 2002 | B2 |
6503276 | Lang et al. | Jan 2003 | B2 |
6517577 | Callahan et al. | Feb 2003 | B1 |
6524340 | Israel | Feb 2003 | B2 |
6537317 | Steinert et al. | Mar 2003 | B1 |
6543453 | Klima et al. | Apr 2003 | B1 |
6547822 | Lang | Apr 2003 | B1 |
6554859 | Lang et al. | Apr 2003 | B1 |
6558395 | Hjertman et al. | May 2003 | B2 |
6558420 | Green | May 2003 | B2 |
6576012 | Lang | Jun 2003 | B2 |
6592621 | Domino | Jul 2003 | B1 |
6596025 | Portney | Jul 2003 | B2 |
6605093 | Blake | Aug 2003 | B1 |
6616692 | Glick et al. | Sep 2003 | B1 |
6638306 | Cumming | Oct 2003 | B2 |
6660035 | Lang et al. | Dec 2003 | B1 |
6666887 | Callahan et al. | Dec 2003 | B1 |
6695881 | Peng et al. | Feb 2004 | B2 |
6730123 | Klopotek | May 2004 | B1 |
6749634 | Hanna | Jun 2004 | B2 |
6755859 | Hoffmann et al. | Jun 2004 | B2 |
6761737 | Zadno-Azizi et al. | Jul 2004 | B2 |
6764511 | Zadno-Azizi et al. | Jul 2004 | B2 |
6767363 | Bandhauer et al. | Jul 2004 | B1 |
6786928 | Callahan et al. | Sep 2004 | B2 |
6786934 | Zadno-Azizi et al. | Sep 2004 | B2 |
6790232 | Lang | Sep 2004 | B1 |
6797003 | Blake et al. | Sep 2004 | B1 |
6800091 | Callahan et al. | Oct 2004 | B2 |
6824563 | Lang | Nov 2004 | B2 |
6836374 | Esch et al. | Dec 2004 | B2 |
6846326 | Zadno-Azizi et al. | Jan 2005 | B2 |
6849091 | Cumming | Feb 2005 | B1 |
6855164 | Glazier | Feb 2005 | B2 |
6858040 | Nguyen et al. | Feb 2005 | B2 |
6860601 | Shadduck | Mar 2005 | B2 |
6884261 | Zadno-Azizi et al. | Apr 2005 | B2 |
6899732 | Zadno-Azizi et al. | May 2005 | B2 |
6918930 | Portney | Jul 2005 | B2 |
6921415 | Callahan et al. | Jul 2005 | B2 |
6921416 | Khoury | Jul 2005 | B2 |
6926736 | Peng et al. | Aug 2005 | B2 |
6926744 | Bos et al. | Aug 2005 | B1 |
6932839 | Kamerling et al. | Aug 2005 | B1 |
6935743 | Shadduck | Aug 2005 | B2 |
6966649 | Shadduck | Nov 2005 | B2 |
6969403 | Peng et al. | Nov 2005 | B2 |
6986763 | Holmen | Jan 2006 | B2 |
6986787 | Baker, Jr. | Jan 2006 | B1 |
6991651 | Portney | Jan 2006 | B2 |
7025783 | Brady et al. | Apr 2006 | B2 |
7036931 | Lindacher et al. | May 2006 | B2 |
7037338 | Nagamoto | May 2006 | B2 |
7041134 | Nguyen et al. | May 2006 | B2 |
7048759 | Bogaert et al. | May 2006 | B2 |
7048760 | Cumming | May 2006 | B2 |
7060094 | Shahinpoor et al. | Jun 2006 | B2 |
7063723 | Ran | Jun 2006 | B2 |
7068439 | Esch et al. | Jun 2006 | B2 |
7087080 | Zadno-Azizi et al. | Aug 2006 | B2 |
7097660 | Portney | Aug 2006 | B2 |
7118596 | Zadno-Azizi et al. | Oct 2006 | B2 |
7118597 | Miller et al. | Oct 2006 | B2 |
7122053 | Esch | Oct 2006 | B2 |
7125422 | Woods et al. | Oct 2006 | B2 |
7137702 | Piers et al. | Nov 2006 | B2 |
7150759 | Paul et al. | Dec 2006 | B2 |
7150760 | Zhang | Dec 2006 | B2 |
7192444 | Blake et al. | Mar 2007 | B2 |
7198640 | Nguyen | Apr 2007 | B2 |
7204849 | Portney | Apr 2007 | B2 |
7217288 | Esch et al. | May 2007 | B2 |
7220279 | Nun | May 2007 | B2 |
7226478 | Ting et al. | Jun 2007 | B2 |
7229475 | Glazier | Jun 2007 | B2 |
7238201 | Portney et al. | Jul 2007 | B2 |
7247168 | Esch et al. | Jul 2007 | B2 |
7261737 | Esch et al. | Aug 2007 | B2 |
7264351 | Shadduck | Sep 2007 | B2 |
7278739 | Shadduck | Oct 2007 | B2 |
7354451 | Koch | Apr 2008 | B2 |
7377640 | Piers et al. | May 2008 | B2 |
7381221 | Lang et al. | Jun 2008 | B2 |
7384429 | Hanna | Jun 2008 | B2 |
7404637 | Miller et al. | Jul 2008 | B2 |
7404638 | Miller et al. | Jul 2008 | B2 |
7435259 | Cumming | Oct 2008 | B2 |
7438723 | Esch | Oct 2008 | B2 |
7452362 | Zadno-Azizi et al. | Nov 2008 | B2 |
7452378 | Zadno-Azizi et al. | Nov 2008 | B2 |
7455691 | Feingold et al. | Nov 2008 | B2 |
7462193 | Nagamoto | Dec 2008 | B2 |
7485144 | Esch | Feb 2009 | B2 |
7494505 | Kappelhof et al. | Feb 2009 | B2 |
7503938 | Phillips | Mar 2009 | B2 |
7553327 | Cumming | Jun 2009 | B2 |
7569073 | Vaudant et al. | Aug 2009 | B2 |
7591849 | Richardson | Sep 2009 | B2 |
7601169 | Phillips | Oct 2009 | B2 |
7615056 | Ayton et al. | Nov 2009 | B2 |
7615073 | Deacon et al. | Nov 2009 | B2 |
7621949 | Deacon et al. | Nov 2009 | B2 |
7637947 | Smith et al. | Dec 2009 | B2 |
7662179 | Sarfarazi | Feb 2010 | B2 |
7670371 | Piers et al. | Mar 2010 | B2 |
7674288 | Nagamoto | Mar 2010 | B2 |
7713299 | Brady et al. | May 2010 | B2 |
7722670 | Elahi et al. | May 2010 | B2 |
7744646 | Zadno-Azizi et al. | Jun 2010 | B2 |
7744647 | Barrett | Jun 2010 | B2 |
7763069 | Brady et al. | Jul 2010 | B2 |
7763070 | Cumming | Jul 2010 | B2 |
7771471 | Dell | Aug 2010 | B2 |
7776088 | Shadduck | Aug 2010 | B2 |
7780729 | Nguyen et al. | Aug 2010 | B2 |
7790824 | Freeman | Sep 2010 | B2 |
7790825 | Lehman et al. | Sep 2010 | B2 |
7794497 | Brady et al. | Sep 2010 | B2 |
7794498 | Pinchuk | Sep 2010 | B2 |
7806930 | Brown | Oct 2010 | B2 |
7811320 | Werblin | Oct 2010 | B2 |
7815678 | Ben Nun | Oct 2010 | B2 |
7837730 | Cumming et al. | Nov 2010 | B2 |
7842087 | Ben Nun | Nov 2010 | B2 |
7854764 | Ben Nun | Dec 2010 | B2 |
7857850 | Mentak et al. | Dec 2010 | B2 |
7871437 | Hermans et al. | Jan 2011 | B2 |
7878655 | Salvati et al. | Feb 2011 | B2 |
7883540 | Niwa et al. | Feb 2011 | B2 |
7905917 | Altmann | Mar 2011 | B2 |
7931686 | Vaudant et al. | Apr 2011 | B2 |
7942889 | Assia | May 2011 | B2 |
7981155 | Cumming | Jul 2011 | B2 |
7985253 | Cumming | Jul 2011 | B2 |
7998198 | Angelopoulos et al. | Aug 2011 | B2 |
7998199 | Ben Nun | Aug 2011 | B2 |
8012204 | Weinschenk, III et al. | Sep 2011 | B2 |
8034106 | Mentak et al. | Oct 2011 | B2 |
8034107 | Stenger | Oct 2011 | B2 |
8034108 | Bumbalough | Oct 2011 | B2 |
8038711 | Clarke | Oct 2011 | B2 |
8043370 | Bretthauer et al. | Oct 2011 | B2 |
8043372 | Bumbalough | Oct 2011 | B2 |
8048155 | Shadduck | Nov 2011 | B2 |
8048156 | Geraghty et al. | Nov 2011 | B2 |
8052752 | Woods et al. | Nov 2011 | B2 |
8062361 | Nguyen et al. | Nov 2011 | B2 |
8062362 | Brady et al. | Nov 2011 | B2 |
8066768 | Werblin | Nov 2011 | B2 |
8066769 | Werblin | Nov 2011 | B2 |
8070806 | Khoury | Dec 2011 | B2 |
8080017 | Tanaka | Dec 2011 | B2 |
8100965 | Cumming et al. | Jan 2012 | B2 |
8109998 | Cumming | Feb 2012 | B2 |
8123729 | Yamamoto et al. | Feb 2012 | B2 |
8133273 | Aharoni et al. | Mar 2012 | B2 |
8158712 | Your | Apr 2012 | B2 |
8163015 | Cumming | Apr 2012 | B2 |
8167941 | Boyd et al. | May 2012 | B2 |
8182531 | Hermans et al. | May 2012 | B2 |
8187325 | Zadno-Azizi et al. | May 2012 | B2 |
8206442 | Sel et al. | Jun 2012 | B2 |
8215770 | Blum et al. | Jul 2012 | B2 |
8216305 | Salvati et al. | Jul 2012 | B2 |
8216306 | Coroneo | Jul 2012 | B2 |
8216308 | Blake et al. | Jul 2012 | B2 |
8231672 | Deacon et al. | Jul 2012 | B2 |
8235525 | Lesage et al. | Aug 2012 | B2 |
8241353 | Deacon et al. | Aug 2012 | B2 |
8241355 | Brady et al. | Aug 2012 | B2 |
8246679 | Nguyen et al. | Aug 2012 | B2 |
8267996 | Niwa et al. | Sep 2012 | B2 |
8273123 | Ben Nun | Sep 2012 | B2 |
8303656 | Shadduck | Nov 2012 | B2 |
8314927 | Choi et al. | Nov 2012 | B2 |
8328869 | Smiley et al. | Dec 2012 | B2 |
8343216 | Brady et al. | Jan 2013 | B2 |
8343217 | Bumbalough | Jan 2013 | B2 |
8349006 | Zhao et al. | Jan 2013 | B2 |
8357196 | Jain et al. | Jan 2013 | B2 |
8361145 | Scholl et al. | Jan 2013 | B2 |
8366653 | Shareef et al. | Feb 2013 | B2 |
8377123 | Evans et al. | Feb 2013 | B2 |
8377125 | Kellan | Feb 2013 | B2 |
8382831 | Ben Nun | Feb 2013 | B2 |
8382832 | Deacon et al. | Feb 2013 | B2 |
8398709 | Ben Nun | Mar 2013 | B2 |
8403984 | Tsai et al. | Mar 2013 | B2 |
8414646 | De Juan, Jr. et al. | Apr 2013 | B2 |
8425595 | Tsai et al. | Apr 2013 | B2 |
8425597 | Glick et al. | Apr 2013 | B2 |
8425598 | Klink et al. | Apr 2013 | B2 |
8425599 | Shadduck | Apr 2013 | B2 |
8430928 | Liao | Apr 2013 | B2 |
8435289 | Cole et al. | May 2013 | B2 |
8447086 | Hildebrand et al. | May 2013 | B2 |
8449611 | Richardson | May 2013 | B2 |
8454688 | Esch et al. | Jun 2013 | B2 |
8465544 | Brady et al. | Jun 2013 | B2 |
8475527 | Peterson et al. | Jul 2013 | B2 |
8475529 | Clarke | Jul 2013 | B2 |
8480734 | Kellan et al. | Jul 2013 | B2 |
8486140 | Willis et al. | Jul 2013 | B2 |
8486141 | Lang et al. | Jul 2013 | B2 |
8486142 | Bumbalough et al. | Jul 2013 | B2 |
8496701 | Hermans et al. | Jul 2013 | B2 |
8500804 | Brady et al. | Aug 2013 | B2 |
8500806 | Phillips | Aug 2013 | B1 |
8523942 | Cumming | Sep 2013 | B2 |
8529623 | Piers et al. | Sep 2013 | B2 |
8535376 | Altmann | Sep 2013 | B2 |
8545556 | Woods et al. | Oct 2013 | B2 |
8551164 | Willis et al. | Oct 2013 | B2 |
8551167 | Cuevas | Oct 2013 | B2 |
8556967 | Sarfarazi | Oct 2013 | B2 |
8562674 | Cole et al. | Oct 2013 | B2 |
8568478 | Zickler et al. | Oct 2013 | B2 |
8574293 | Kappelhof et al. | Nov 2013 | B2 |
8579971 | Webb | Nov 2013 | B2 |
8579972 | Rombach | Nov 2013 | B2 |
8585758 | Woods | Nov 2013 | B2 |
8585759 | Bumbalough | Nov 2013 | B2 |
8608799 | Blake | Dec 2013 | B2 |
8608800 | Portney | Dec 2013 | B2 |
8613766 | Richardson et al. | Dec 2013 | B2 |
8623082 | Kappelhof et al. | Jan 2014 | B2 |
8647384 | Lu | Feb 2014 | B2 |
8652206 | Masket | Feb 2014 | B2 |
8657877 | Glazier | Feb 2014 | B2 |
8657878 | Mentak et al. | Feb 2014 | B2 |
8668734 | Hildebrand et al. | Mar 2014 | B2 |
8900298 | Anvar et al. | Dec 2014 | B2 |
8956408 | Smiley et al. | Feb 2015 | B2 |
8968396 | Matthews et al. | Mar 2015 | B2 |
8992609 | Shadduck | Mar 2015 | B2 |
9044317 | Hildebrand et al. | Jun 2015 | B2 |
9072600 | Tran | Jul 2015 | B2 |
9186244 | Silvestrini et al. | Nov 2015 | B2 |
9220590 | Beer | Dec 2015 | B2 |
9277987 | Smiley et al. | Mar 2016 | B2 |
9364318 | Beer | Jun 2016 | B2 |
9456895 | Shadduck | Oct 2016 | B2 |
9610155 | Matthews | Apr 2017 | B2 |
9693858 | Hildebrand et al. | Jul 2017 | B2 |
9795473 | Smiley et al. | Oct 2017 | B2 |
9855137 | Smiley et al. | Jan 2018 | B2 |
9855139 | Matthews et al. | Jan 2018 | B2 |
9872762 | Scholl et al. | Jan 2018 | B2 |
9872763 | Smiley et al. | Jan 2018 | B2 |
10004596 | Brady et al. | Jun 2018 | B2 |
10045844 | Smiley et al. | Aug 2018 | B2 |
10111745 | Silvestrini et al. | Oct 2018 | B2 |
10159564 | Brady et al. | Dec 2018 | B2 |
10195020 | Matthews | Feb 2019 | B2 |
20010001836 | Cumming | May 2001 | A1 |
20010012964 | Lang et al. | Aug 2001 | A1 |
20010016771 | Cumming | Aug 2001 | A1 |
20010044657 | Kellan | Nov 2001 | A1 |
20010051826 | Bogaert et al. | Dec 2001 | A1 |
20020002404 | Sarfarazi | Jan 2002 | A1 |
20020013622 | Hennig | Jan 2002 | A1 |
20020016630 | Lang | Feb 2002 | A1 |
20020045937 | Sarfarazi | Apr 2002 | A1 |
20020051063 | Hwang | May 2002 | A1 |
20020072673 | Yamamoto et al. | Jun 2002 | A1 |
20020072795 | Green | Jun 2002 | A1 |
20020101564 | Herrick | Aug 2002 | A1 |
20020103535 | Portney | Aug 2002 | A1 |
20020107568 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020111678 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116057 | Ting et al. | Aug 2002 | A1 |
20020116058 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116059 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116060 | Nguyen et al. | Aug 2002 | A1 |
20020116061 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116062 | Portney | Aug 2002 | A1 |
20020133228 | Sarver | Sep 2002 | A1 |
20020138140 | Hanna | Sep 2002 | A1 |
20020138141 | Zadno-Azizi et al. | Sep 2002 | A1 |
20020143395 | Skottun | Oct 2002 | A1 |
20020161435 | Portney | Oct 2002 | A1 |
20020173847 | Pham et al. | Nov 2002 | A1 |
20020177896 | Israel | Nov 2002 | A1 |
20020183843 | Blake et al. | Dec 2002 | A1 |
20020193876 | Lang et al. | Dec 2002 | A1 |
20020193877 | Hoffmann et al. | Dec 2002 | A1 |
20030018386 | Laguette et al. | Jan 2003 | A1 |
20030033011 | Singer et al. | Feb 2003 | A1 |
20030033013 | Callahan et al. | Feb 2003 | A1 |
20030060878 | Shadduck | Mar 2003 | A1 |
20030065387 | Callahan et al. | Apr 2003 | A1 |
20030074060 | Zadno-Azizi et al. | Apr 2003 | A1 |
20030074061 | Pham et al. | Apr 2003 | A1 |
20030078655 | Callahan et al. | Apr 2003 | A1 |
20030078656 | Nguyen | Apr 2003 | A1 |
20030078657 | Zadno-Azizi et al. | Apr 2003 | A1 |
20030078658 | Zadno-Azizi | Apr 2003 | A1 |
20030083744 | Khoury | May 2003 | A1 |
20030093149 | Glazier | May 2003 | A1 |
20030105522 | Glazier | Jun 2003 | A1 |
20030109926 | Portney | Jun 2003 | A1 |
20030114927 | Nagamoto | Jun 2003 | A1 |
20030130732 | Sarfarazi | Jul 2003 | A1 |
20030135271 | Bandhauer | Jul 2003 | A1 |
20030135273 | Callahan et al. | Jul 2003 | A1 |
20030147046 | Shadduck | Aug 2003 | A1 |
20030149480 | Shadduck | Aug 2003 | A1 |
20030171808 | Phillips | Sep 2003 | A1 |
20030171809 | Phillips | Sep 2003 | A1 |
20030181977 | Brady | Sep 2003 | A1 |
20030187504 | Weinschenk et al. | Oct 2003 | A1 |
20030199976 | Portney | Oct 2003 | A1 |
20030204254 | Peng et al. | Oct 2003 | A1 |
20030204255 | Peng et al. | Oct 2003 | A1 |
20030204256 | Peng et al. | Oct 2003 | A1 |
20040015236 | Sarfarazi et al. | Jan 2004 | A1 |
20040034417 | Heyman | Feb 2004 | A1 |
20040064182 | Kelman | Apr 2004 | A1 |
20040073304 | Weinschenk, III et al. | Apr 2004 | A1 |
20040082993 | Woods | Apr 2004 | A1 |
20040082994 | Woods et al. | Apr 2004 | A1 |
20040082995 | Woods | Apr 2004 | A1 |
20040100704 | Shadduck | May 2004 | A1 |
20040106992 | Lang et al. | Jun 2004 | A1 |
20040106993 | Portney | Jun 2004 | A1 |
20040111152 | Kelman | Jun 2004 | A1 |
20040111153 | Woods et al. | Jun 2004 | A1 |
20040117013 | Schachar | Jun 2004 | A1 |
20040158322 | Shen | Aug 2004 | A1 |
20040162612 | Portney et al. | Aug 2004 | A1 |
20040169816 | Esch | Sep 2004 | A1 |
20040169932 | Esch et al. | Sep 2004 | A1 |
20040181279 | Nun | Sep 2004 | A1 |
20040184158 | Shadduck | Sep 2004 | A1 |
20040190153 | Esch | Sep 2004 | A1 |
20040215340 | Messner et al. | Oct 2004 | A1 |
20040230300 | Bandhauer et al. | Nov 2004 | A1 |
20040236422 | Zhang et al. | Nov 2004 | A1 |
20040236423 | Zhang et al. | Nov 2004 | A1 |
20040243233 | Phillips | Dec 2004 | A1 |
20040249455 | Tran | Dec 2004 | A1 |
20050021137 | Blake et al. | Jan 2005 | A1 |
20050021138 | Woods | Jan 2005 | A1 |
20050021139 | Shadduck | Jan 2005 | A1 |
20050049700 | Zadno-Azizi et al. | Mar 2005 | A1 |
20050055092 | Nguyen et al. | Mar 2005 | A1 |
20050060032 | Magnante et al. | Mar 2005 | A1 |
20050071002 | Glazier | Mar 2005 | A1 |
20050075732 | Israel | Apr 2005 | A1 |
20050085907 | Hanna | Apr 2005 | A1 |
20050090896 | Ben Nun | Apr 2005 | A1 |
20050096741 | Cumming | May 2005 | A1 |
20050107873 | Zhou | May 2005 | A1 |
20050107875 | Cumming | May 2005 | A1 |
20050113914 | Miller et al. | May 2005 | A1 |
20050119739 | Glazier | Jun 2005 | A1 |
20050119740 | Esch et al. | Jun 2005 | A1 |
20050125055 | Deacon et al. | Jun 2005 | A1 |
20050125057 | Cumming | Jun 2005 | A1 |
20050125059 | Pinchuk et al. | Jun 2005 | A1 |
20050131535 | Woods | Jun 2005 | A1 |
20050137703 | Chen | Jun 2005 | A1 |
20050143814 | Esch et al. | Jun 2005 | A1 |
20050149183 | Shadduck | Jul 2005 | A1 |
20050149184 | Bogaert | Jul 2005 | A1 |
20050209692 | Zhang | Sep 2005 | A1 |
20050234547 | Nguyen et al. | Oct 2005 | A1 |
20050251254 | Brady et al. | Nov 2005 | A1 |
20050267575 | Nguyen et al. | Dec 2005 | A1 |
20060020339 | Ran | Jan 2006 | A1 |
20060030938 | Altmann | Feb 2006 | A1 |
20060041307 | Esch et al. | Feb 2006 | A1 |
20060047339 | Brown | Mar 2006 | A1 |
20060047340 | Brown | Mar 2006 | A1 |
20060061729 | Shadduck | Mar 2006 | A1 |
20060064162 | Klima | Mar 2006 | A1 |
20060069433 | Nun | Mar 2006 | A1 |
20060087614 | Shadduck | Apr 2006 | A1 |
20060089712 | Malecaze | Apr 2006 | A1 |
20060092340 | Blum et al. | May 2006 | A1 |
20060100701 | Esch et al. | May 2006 | A1 |
20060100703 | Evans et al. | May 2006 | A1 |
20060100704 | Blake et al. | May 2006 | A1 |
20060116765 | Blake et al. | Jun 2006 | A1 |
20060142855 | Vaudant et al. | Jun 2006 | A1 |
20060149369 | Cumming et al. | Jul 2006 | A1 |
20060178741 | Zadno-Azizi et al. | Aug 2006 | A1 |
20060178742 | Nagamoto | Aug 2006 | A1 |
20060184244 | Nguyen et al. | Aug 2006 | A1 |
20060212116 | Woods | Sep 2006 | A1 |
20060212117 | Lang et al. | Sep 2006 | A1 |
20060247766 | Marin | Nov 2006 | A1 |
20060247767 | Koch | Nov 2006 | A1 |
20060253196 | Woods | Nov 2006 | A1 |
20060259139 | Zadno-Azizi et al. | Nov 2006 | A1 |
20060259140 | Dell | Nov 2006 | A1 |
20060271186 | Nishi et al. | Nov 2006 | A1 |
20060271187 | Zadno-Azizi et al. | Nov 2006 | A1 |
20070005135 | Makker et al. | Jan 2007 | A1 |
20070005136 | Richardson | Jan 2007 | A1 |
20070010880 | Esch | Jan 2007 | A1 |
20070010882 | Barrett | Jan 2007 | A1 |
20070016293 | Tran | Jan 2007 | A1 |
20070021831 | Clarke | Jan 2007 | A1 |
20070021832 | Nordan | Jan 2007 | A1 |
20070027540 | Zadno-Azizi et al. | Feb 2007 | A1 |
20070032866 | Portney | Feb 2007 | A1 |
20070050024 | Zhang | Mar 2007 | A1 |
20070050025 | Nguyen et al. | Mar 2007 | A1 |
20070067030 | Glazier et al. | Mar 2007 | A1 |
20070078515 | Brady | Apr 2007 | A1 |
20070083260 | Colvard | Apr 2007 | A1 |
20070083261 | Colvard | Apr 2007 | A1 |
20070088433 | Esch et al. | Apr 2007 | A1 |
20070100444 | Brady et al. | May 2007 | A1 |
20070100445 | Shadduck | May 2007 | A1 |
20070106377 | Smith et al. | May 2007 | A1 |
20070106380 | Terwee et al. | May 2007 | A1 |
20070106381 | Blake | May 2007 | A1 |
20070108643 | Zadno-Azizi et al. | May 2007 | A1 |
20070118216 | Pynson | May 2007 | A1 |
20070123981 | Tassignon | May 2007 | A1 |
20070129798 | Chawdhary | Jun 2007 | A1 |
20070129803 | Cumming et al. | Jun 2007 | A1 |
20070135915 | Klima | Jun 2007 | A1 |
20070142913 | Phillips | Jun 2007 | A1 |
20070156236 | Stenger | Jul 2007 | A1 |
20070171366 | Su et al. | Jul 2007 | A1 |
20070185574 | Ben Nun | Aug 2007 | A1 |
20070203578 | Scholl et al. | Aug 2007 | A1 |
20070213817 | Esch et al. | Sep 2007 | A1 |
20070239274 | Kellan | Oct 2007 | A1 |
20070244560 | Ossipov et al. | Oct 2007 | A1 |
20070244561 | Ben Nun | Oct 2007 | A1 |
20070260308 | Tran | Nov 2007 | A1 |
20070260309 | Richardson | Nov 2007 | A1 |
20070260310 | Richardson | Nov 2007 | A1 |
20070270946 | Poley | Nov 2007 | A1 |
20070299487 | Shadduck | Dec 2007 | A1 |
20080004699 | Ben Nun | Jan 2008 | A1 |
20080015689 | Esch et al. | Jan 2008 | A1 |
20080021549 | Eagan et al. | Jan 2008 | A1 |
20080021550 | Richardson | Jan 2008 | A1 |
20080033449 | Cole et al. | Feb 2008 | A1 |
20080046074 | Smith et al. | Feb 2008 | A1 |
20080046075 | Esch et al. | Feb 2008 | A1 |
20080046076 | Rombach | Feb 2008 | A1 |
20080051801 | Hovey et al. | Feb 2008 | A1 |
20080077238 | Deacon et al. | Mar 2008 | A1 |
20080077239 | Zickler et al. | Mar 2008 | A1 |
20080086206 | Nasiatka et al. | Apr 2008 | A1 |
20080086208 | Nordan | Apr 2008 | A1 |
20080109077 | Bos | May 2008 | A1 |
20080109078 | Rozakis et al. | May 2008 | A1 |
20080154364 | Richardson et al. | Jun 2008 | A1 |
20080161913 | Brady et al. | Jul 2008 | A1 |
20080161914 | Brady et al. | Jul 2008 | A1 |
20080183289 | Werblin | Jul 2008 | A1 |
20080188930 | Mentak et al. | Aug 2008 | A1 |
20080200982 | Your | Aug 2008 | A1 |
20080208335 | Blum et al. | Aug 2008 | A1 |
20080215147 | Werblin | Sep 2008 | A1 |
20080243247 | Poley et al. | Oct 2008 | A1 |
20080269642 | Deacon et al. | Oct 2008 | A1 |
20080269882 | Simpson et al. | Oct 2008 | A1 |
20080269885 | Simpson et al. | Oct 2008 | A1 |
20080269886 | Simpson et al. | Oct 2008 | A1 |
20080281417 | Nagamoto | Nov 2008 | A1 |
20080300680 | Joshua | Dec 2008 | A1 |
20080306587 | Your | Dec 2008 | A1 |
20080306588 | Smiley et al. | Dec 2008 | A1 |
20090005865 | Smiley et al. | Jan 2009 | A1 |
20090005866 | Cumming | Jan 2009 | A1 |
20090012609 | Geraghty et al. | Jan 2009 | A1 |
20090018652 | Hermans et al. | Jan 2009 | A1 |
20090027661 | Choi et al. | Jan 2009 | A1 |
20090030425 | Smiley et al. | Jan 2009 | A1 |
20090033863 | Blum et al. | Feb 2009 | A1 |
20090036982 | Aharoni et al. | Feb 2009 | A1 |
20090062912 | Rombach | Mar 2009 | A1 |
20090124773 | Zhou et al. | May 2009 | A1 |
20090125105 | Lesage et al. | May 2009 | A1 |
20090125106 | Weinschenk, III et al. | May 2009 | A1 |
20090149952 | Shadduck | Jun 2009 | A1 |
20090171458 | Kellan et al. | Jul 2009 | A1 |
20090187242 | Weeber et al. | Jul 2009 | A1 |
20090198326 | Zhou et al. | Aug 2009 | A1 |
20090204209 | Tran | Aug 2009 | A1 |
20090204210 | Pynson | Aug 2009 | A1 |
20090204211 | Angelopoulos et al. | Aug 2009 | A1 |
20090210054 | Weeber et al. | Aug 2009 | A1 |
20090228101 | Zadno-Azizi | Sep 2009 | A1 |
20090234448 | Weeber et al. | Sep 2009 | A1 |
20090234449 | De Juan, Jr. et al. | Sep 2009 | A1 |
20090248152 | Bumbalough | Oct 2009 | A1 |
20090248154 | Dell | Oct 2009 | A1 |
20090264998 | Mentak et al. | Oct 2009 | A1 |
20090264999 | Cumming | Oct 2009 | A1 |
20090265000 | Vaudant et al. | Oct 2009 | A1 |
20090292354 | Gontijo et al. | Nov 2009 | A1 |
20090292355 | Boyd et al. | Nov 2009 | A1 |
20090312836 | Pinchuk et al. | Dec 2009 | A1 |
20090319040 | Khoury | Dec 2009 | A1 |
20100016964 | Werblin | Jan 2010 | A1 |
20100036490 | Deacon et al. | Feb 2010 | A1 |
20100094412 | Wensrich | Apr 2010 | A1 |
20100094415 | Bumbalough | Apr 2010 | A1 |
20100121443 | Michel et al. | May 2010 | A1 |
20100121444 | Ben Nun | May 2010 | A1 |
20100131058 | Shadduck | May 2010 | A1 |
20100131059 | Callahan et al. | May 2010 | A1 |
20100131061 | Callahan et al. | May 2010 | A1 |
20100134754 | Hong et al. | Jun 2010 | A1 |
20100137983 | Culbertson et al. | Jun 2010 | A1 |
20100152848 | Williamson et al. | Jun 2010 | A1 |
20100179652 | Yamamoto et al. | Jul 2010 | A1 |
20100179653 | Argento et al. | Jul 2010 | A1 |
20100198349 | Brady et al. | Aug 2010 | A1 |
20100204788 | Van Noy | Aug 2010 | A1 |
20100211167 | Glazier | Aug 2010 | A1 |
20100211170 | Liao | Aug 2010 | A1 |
20100211171 | Sarfarazi | Aug 2010 | A1 |
20100228260 | Callahan et al. | Sep 2010 | A1 |
20100228344 | Shadduck | Sep 2010 | A1 |
20100228346 | Esch | Sep 2010 | A1 |
20100292789 | Willis et al. | Nov 2010 | A1 |
20100318186 | Bumbalough et al. | Dec 2010 | A1 |
20100324671 | Shadduck | Dec 2010 | A1 |
20100324672 | Esch et al. | Dec 2010 | A1 |
20100324673 | Nguyen et al. | Dec 2010 | A1 |
20110029074 | Reisin et al. | Feb 2011 | A1 |
20110035001 | Woods | Feb 2011 | A1 |
20110035002 | Nun | Feb 2011 | A1 |
20110040376 | Christie et al. | Feb 2011 | A1 |
20110040378 | Werblin | Feb 2011 | A1 |
20110040379 | Bumbalough | Feb 2011 | A1 |
20110052020 | Hildebrand et al. | Mar 2011 | A1 |
20110054600 | Bumbalough | Mar 2011 | A1 |
20110054601 | Kadziauskas et al. | Mar 2011 | A1 |
20110071628 | Gross et al. | Mar 2011 | A1 |
20110082544 | Ben Nun | Apr 2011 | A1 |
20110093067 | Michalek et al. | Apr 2011 | A1 |
20110098810 | Altmann | Apr 2011 | A1 |
20110098812 | Ben Nun | Apr 2011 | A1 |
20110112635 | Ben Nun | May 2011 | A1 |
20110112636 | Ben Nun | May 2011 | A1 |
20110112638 | Hermans et al. | May 2011 | A1 |
20110118836 | Jain et al. | May 2011 | A1 |
20110153014 | Zhang et al. | Jun 2011 | A1 |
20110153015 | Simonov et al. | Jun 2011 | A1 |
20110160852 | Mentak et al. | Jun 2011 | A1 |
20110184514 | Angelopoulos et al. | Jul 2011 | A1 |
20110191086 | Callahan et al. | Aug 2011 | A1 |
20110208301 | Anvar et al. | Aug 2011 | A1 |
20110224788 | Webb | Sep 2011 | A1 |
20110238174 | Hong et al. | Sep 2011 | A1 |
20110245920 | Richardson | Oct 2011 | A1 |
20110251686 | Masket | Oct 2011 | A1 |
20110257742 | Bumbalough et al. | Oct 2011 | A1 |
20110270389 | Glazer et al. | Nov 2011 | A1 |
20110282441 | Zadno-Azizi | Nov 2011 | A1 |
20110282442 | Scholl et al. | Nov 2011 | A1 |
20110282443 | Smiley et al. | Nov 2011 | A1 |
20110288638 | Smiley et al. | Nov 2011 | A1 |
20110295368 | Betser | Dec 2011 | A1 |
20110304058 | Pendse | Dec 2011 | A1 |
20110307058 | Beer | Dec 2011 | A1 |
20110313522 | Hayes | Dec 2011 | A1 |
20110313523 | Hayes | Dec 2011 | A1 |
20120010704 | Bumbalough | Jan 2012 | A1 |
20120016473 | Brady et al. | Jan 2012 | A1 |
20120022547 | Hildebrand et al. | Jan 2012 | A1 |
20120029632 | Ben Nun | Feb 2012 | A1 |
20120035724 | Clarke | Feb 2012 | A1 |
20120046743 | Pinchuk | Feb 2012 | A1 |
20120046744 | Woods et al. | Feb 2012 | A1 |
20120059465 | Brady et al. | Mar 2012 | A1 |
20120078361 | Shadduck | Mar 2012 | A1 |
20120078363 | Lu | Mar 2012 | A1 |
20120078364 | Stenger | Mar 2012 | A1 |
20120116506 | Compertore | May 2012 | A1 |
20120130487 | Doraiswamy et al. | May 2012 | A1 |
20120130488 | Doraiswamy et al. | May 2012 | A1 |
20120143327 | Bumbalough | Jun 2012 | A1 |
20120150292 | Mentak et al. | Jun 2012 | A1 |
20120203338 | Jain | Aug 2012 | A1 |
20120232648 | Kahook et al. | Sep 2012 | A1 |
20120232650 | Hermans et al. | Sep 2012 | A1 |
20120232651 | Kahook et al. | Sep 2012 | A1 |
20120245591 | Matthews | Sep 2012 | A1 |
20120245684 | Liao | Sep 2012 | A1 |
20120253458 | Geraghty et al. | Oct 2012 | A1 |
20120253459 | Reich et al. | Oct 2012 | A1 |
20120290084 | Coroneo | Nov 2012 | A1 |
20120296425 | Cumming | Nov 2012 | A1 |
20120296426 | Brady et al. | Nov 2012 | A1 |
20120303119 | Callahan et al. | Nov 2012 | A1 |
20120310338 | Christie et al. | Dec 2012 | A1 |
20120310342 | Nguyen et al. | Dec 2012 | A1 |
20120310343 | Van Noy | Dec 2012 | A1 |
20120310344 | Cumming | Dec 2012 | A1 |
20120310345 | Olcina Portilla | Dec 2012 | A1 |
20120323320 | Simonov et al. | Dec 2012 | A1 |
20120323321 | Simonov et al. | Dec 2012 | A1 |
20120330415 | Callahan et al. | Dec 2012 | A1 |
20130013060 | Zadno-Azizi et al. | Jan 2013 | A1 |
20130018461 | Ben Nun | Jan 2013 | A1 |
20130030525 | Brady et al. | Jan 2013 | A1 |
20130035760 | Portney | Feb 2013 | A1 |
20130053954 | Rao et al. | Feb 2013 | A1 |
20130060330 | Weeber et al. | Mar 2013 | A1 |
20130060331 | Shadduck | Mar 2013 | A1 |
20130060332 | Simpson | Mar 2013 | A1 |
20130073039 | Mirlay | Mar 2013 | A1 |
20130103146 | Smiley et al. | Apr 2013 | A1 |
20130103147 | Christie et al. | Apr 2013 | A1 |
20130110235 | Schwiegerling | May 2013 | A1 |
20130116781 | Ben Nun | May 2013 | A1 |
20130131794 | Smiley et al. | May 2013 | A1 |
20130138208 | Simonov et al. | May 2013 | A1 |
20130150961 | Evans et al. | Jun 2013 | A1 |
20130166026 | Bumbalough | Jun 2013 | A1 |
20130184816 | Hayes | Jul 2013 | A1 |
20130190868 | Kahook et al. | Jul 2013 | A1 |
20130197635 | Phillips | Aug 2013 | A1 |
20130204364 | Olson | Aug 2013 | A1 |
20130204365 | Dell | Aug 2013 | A1 |
20130226294 | Van Der Mooren et al. | Aug 2013 | A1 |
20130226295 | de Juan, Jr. et al. | Aug 2013 | A1 |
20130231741 | Clarke | Sep 2013 | A1 |
20130231742 | Deacon et al. | Sep 2013 | A1 |
20130238091 | Danta et al. | Sep 2013 | A1 |
20130245754 | Blum et al. | Sep 2013 | A1 |
20130245756 | Liao | Sep 2013 | A1 |
20130250239 | Hildebrand et al. | Sep 2013 | A1 |
20130268070 | Esch et al. | Oct 2013 | A1 |
20130268071 | Vilupuru et al. | Oct 2013 | A1 |
20130282117 | Van Heugten et al. | Oct 2013 | A1 |
20130297018 | Brady et al. | Nov 2013 | A1 |
20130304202 | Basinger | Nov 2013 | A1 |
20130304203 | Beer | Nov 2013 | A1 |
20130304204 | Bumbalough et al. | Nov 2013 | A1 |
20130310931 | Kahook et al. | Nov 2013 | A1 |
20130310932 | Kellan | Nov 2013 | A1 |
20130317606 | Culbertson et al. | Nov 2013 | A1 |
20130317608 | Hermans et al. | Nov 2013 | A1 |
20130331937 | Stevens | Dec 2013 | A1 |
20130338767 | Mazzocchi et al. | Dec 2013 | A1 |
20130345713 | Cole et al. | Dec 2013 | A1 |
20140005780 | Zhao | Jan 2014 | A1 |
20140005781 | Zhao et al. | Jan 2014 | A1 |
20140005782 | Kellan et al. | Jan 2014 | A1 |
20140012277 | Matthews et al. | Jan 2014 | A1 |
20140052245 | Zickler et al. | Feb 2014 | A1 |
20140052246 | Kahook et al. | Feb 2014 | A1 |
20140058507 | Reich et al. | Feb 2014 | A1 |
20140142588 | Hildebrand et al. | May 2014 | A1 |
20140180403 | Silvestrini et al. | Jun 2014 | A1 |
20140180405 | Weinschenk, III et al. | Jun 2014 | A1 |
20140180406 | Simpson | Jun 2014 | A1 |
20140180407 | Sohn et al. | Jun 2014 | A1 |
20140194859 | Ianchulev | Jul 2014 | A1 |
20140249625 | Shadduck | Sep 2014 | A1 |
20150087743 | Anvar et al. | Mar 2015 | A1 |
20150088254 | Cumming | Mar 2015 | A1 |
20150105760 | Rao et al. | Apr 2015 | A1 |
20150134059 | Curatu | May 2015 | A1 |
20150142108 | Akura et al. | May 2015 | A1 |
20150202041 | Shadduck | Jul 2015 | A1 |
20150238310 | Matthews et al. | Aug 2015 | A1 |
20150257874 | Hildebrand et al. | Sep 2015 | A1 |
20160030161 | Brady et al. | Feb 2016 | A1 |
20160038278 | Matthews | Feb 2016 | A1 |
20160128826 | Silvestrini et al. | May 2016 | A1 |
20160157996 | Dolla et al. | Jun 2016 | A1 |
20160184091 | Smiley et al. | Jun 2016 | A1 |
20160184092 | Smiley et al. | Jun 2016 | A1 |
20160262875 | Smith et al. | Sep 2016 | A1 |
20160317286 | Brady et al. | Nov 2016 | A1 |
20160317287 | Silvestrini et al. | Nov 2016 | A1 |
20160361157 | Honigsbaum | Dec 2016 | A1 |
20170020662 | Shadduck | Jan 2017 | A1 |
20170049561 | Smiley et al. | Feb 2017 | A1 |
20170079773 | Matthews et al. | Mar 2017 | A1 |
20170247525 | Silvestrini et al. | Aug 2017 | A1 |
20170290658 | Hildebrand et al. | Oct 2017 | A1 |
20170342096 | Silvestrini | Nov 2017 | A1 |
20180028308 | Smiley et al. | Feb 2018 | A1 |
20180125640 | Smiley et al. | May 2018 | A1 |
20180147051 | Scholl et al. | May 2018 | A1 |
20180153682 | Hajela et al. | Jun 2018 | A1 |
20180177639 | Rao et al. | Jun 2018 | A1 |
20180256315 | Hildebrand et al. | Sep 2018 | A1 |
20180271645 | Brady et al. | Sep 2018 | A1 |
20180344453 | Brady et al. | Dec 2018 | A1 |
20190000612 | Rao et al. | Jan 2019 | A1 |
20190099263 | Brady et al. | Apr 2019 | A1 |
Number | Date | Country |
---|---|---|
2003294418 | Jun 2004 | AU |
2003297101 | Jun 2004 | AU |
2003300879 | Jul 2004 | AU |
2004211746 | Aug 2004 | AU |
2004219674 | Sep 2004 | AU |
2005299661 | May 2006 | AU |
2006265668 | Jan 2007 | AU |
2006304339 | Apr 2007 | AU |
2007340043 | Jul 2008 | AU |
2008218313 | Aug 2008 | AU |
2008279167 | Jan 2009 | AU |
2008279173 | Jan 2009 | AU |
2010235988 | Nov 2010 | AU |
2010203427 | Jul 2011 | AU |
2012335677 | May 2014 | AU |
2014202532 | Jul 2014 | AU |
2013235467 | Sep 2014 | AU |
2015258287 | Dec 2015 | AU |
2017216460 | Aug 2017 | AU |
2016275073 | Jan 2018 | AU |
2018200978 | Mar 2018 | AU |
2016349532 | Apr 2018 | AU |
2019201556 | Mar 2019 | AU |
2506753 | Jun 2004 | CA |
2508143 | Jun 2004 | CA |
2507694 | Jul 2004 | CA |
2515355 | Aug 2004 | CA |
2584472 | May 2006 | CA |
2613580 | Jan 2007 | CA |
2626269 | Apr 2007 | CA |
2674816 | Jul 2008 | CA |
2676713 | Aug 2008 | CA |
2693906 | Jan 2009 | CA |
2696450 | Jan 2009 | CA |
2748812 | Jul 2010 | CA |
2854919 | May 2013 | CA |
2865954 | Sep 2013 | CA |
2987311 | Dec 2016 | CA |
3001477 | May 2017 | CA |
112010004191 | Nov 2012 | DE |
1563337 | Aug 2005 | EP |
1569581 | Sep 2005 | EP |
1585563 | Oct 2005 | EP |
1590702 | Nov 2005 | EP |
1599748 | Nov 2005 | EP |
1816984 | Aug 2007 | EP |
1906882 | Apr 2008 | EP |
1948084 | Jul 2008 | EP |
2053991 | May 2009 | EP |
2094193 | Sep 2009 | EP |
2112932 | Nov 2009 | EP |
2178462 | Apr 2010 | EP |
2178463 | Apr 2010 | EP |
2178464 | Apr 2010 | EP |
2221024 | Aug 2010 | EP |
2384167 | Nov 2011 | EP |
2473138 | Jul 2012 | EP |
2539351 | Jan 2013 | EP |
2559405 | Feb 2013 | EP |
2563275 | Mar 2013 | EP |
2647353 | Oct 2013 | EP |
2671541 | Dec 2013 | EP |
2688515 | Jan 2014 | EP |
2775961 | Sep 2014 | EP |
2827804 | Jan 2015 | EP |
2934383 | Oct 2015 | EP |
2967842 | Jan 2016 | EP |
3049023 | Aug 2016 | EP |
3062741 | Sep 2016 | EP |
3062742 | Sep 2016 | EP |
3174500 | Jun 2017 | EP |
3181094 | Jun 2017 | EP |
3197462 | Aug 2017 | EP |
3263574 | Jan 2018 | EP |
3307206 | Apr 2018 | EP |
3370647 | Sep 2018 | EP |
3383320 | Oct 2018 | EP |
1583193 | Jan 1981 | GB |
1227277 | Oct 2017 | HK |
1227679 | Oct 2017 | HK |
1234303 | Feb 2018 | HK |
1235658 | Mar 2018 | HK |
1239501 | May 2018 | HK |
1241712 | Jun 2018 | HK |
1242207 | Jun 2018 | HK |
6305DELNP2015 | Jul 2016 | IN |
201617018083 | Aug 2016 | IN |
201717013927 | Aug 2017 | IN |
201617044673 | Feb 2018 | IN |
2014061387 | Apr 2014 | JP |
2012420 | Sep 2014 | NL |
WO-2004046768 | Jun 2004 | WO |
WO-2004052242 | Jun 2004 | WO |
WO-2004054471 | Jul 2004 | WO |
WO-2004072689 | Aug 2004 | WO |
WO-2006047383 | May 2006 | WO |
WO-2007005778 | Jan 2007 | WO |
WO-2007047529 | Apr 2007 | WO |
WO-2007047530 | Apr 2007 | WO |
WO-2008024766 | Feb 2008 | WO |
WO-2008077040 | Jun 2008 | WO |
WO-2008082957 | Jul 2008 | WO |
WO-2008103798 | Aug 2008 | WO |
WO-2009015161 | Jan 2009 | WO |
WO-2009015226 | Jan 2009 | WO |
WO-2009015234 | Jan 2009 | WO |
WO-2009015240 | Jan 2009 | WO |
WO-2010081093 | Jul 2010 | WO |
WO-2011026068 | Mar 2011 | WO |
WO-2011106435 | Sep 2011 | WO |
WO-2011137191 | Nov 2011 | WO |
WO-2012006616 | Jan 2012 | WO |
WO-20120106673 | Aug 2012 | WO |
WO-2012129407 | Sep 2012 | WO |
WO-2013070924 | May 2013 | WO |
WO-2013142323 | Sep 2013 | WO |
WO-2013166068 | Nov 2013 | WO |
WO-2014099630 | Jun 2014 | WO |
WO-2014134302 | Sep 2014 | WO |
WO-2014145562 | Sep 2014 | WO |
WO-2015148673 | Oct 2015 | WO |
WO-2016018932 | Feb 2016 | WO |
WO-2016049059 | Mar 2016 | WO |
WO-2016201351 | Dec 2016 | WO |
WO-2017079733 | May 2017 | WO |
WO-2017085344 | May 2017 | WO |
Entry |
---|
International Search Report and Written Opinion dated Dec. 4, 2013 in International Application No. PCT/US2013/039708. |
Invitation to Pay Additional Fees dated Sep. 17, 2013 in International Application No. PCT/US2013/039708. |
International Preliminary Report on Patentability and Written Opinion dated Nov. 20, 2014 in International Application No. PCT/US2013/039708 (13 pages). |
Communication Pursuant to Rule 164(2) and Article 94(3) dated Oct. 11, 2018, for Application No. 13725509.7, 9 pg. |
International Search Report and Written Opinion in PCT/US2017/048219 dated Jan. 2, 2018, 19 pages. |
Communication Pursued to Article 94(3) EPC dated Oct. 11, 2018 in European Patent Application No. 13725509.7, 9 pages. |
Communication Pursued to Article 94(3) EPC dated Apr. 2, 2019 in European Patent Application No. 17772509.0, 3 pages. |
Number | Date | Country | |
---|---|---|---|
20180055626 A1 | Mar 2018 | US |
Number | Date | Country | |
---|---|---|---|
62378737 | Aug 2016 | US |